Benjamin Blumel

Benjamin Blumel

Auto-generated profile, based on publicly available information

Benjamin Blumel

FIND , Geneva

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2023 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
CTChristos Thomadakis
Christos Thomadakis
IGIlias Gountas
Ilias Gountas
EDErika Duffell
Erika Duffell
KGKonstantinos Gountas
Konstantinos Gountas
BBBenjamin Bluemel
Benjamin Bluemel
Georgios NikolopoulosGeorgios Nikolopoulos
Georgios Nikolopoulos
Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = πrecρrec + πexρex + πnonρnon; πrec, πex, and πnon represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρrec, ρex, and ρnon represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID. 10.13039/501100000805 ECDC .

9 January 2024 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
LVLindsey de Vos
Lindsey de Vos
JDJoseph Daniels
Joseph Daniels
AGAvuyonke Gebengu
Avuyonke Gebengu
LMLaura Mazzola
Laura Mazzola
BGBirgitta Gleeson
Birgitta Gleeson
RPRemco Peters
Remco Peters
Background: South Africa maintains an integrated health system where syndromic management of sexually transmitted infections (STI) is the standard of care. An estimated 2 million cases ofNeisseria gonorrhoeae (N. gonorrhoeae)occur in South Africa every year. Point-of-care diagnostic tests (POCT) may address existing STI control limitations such as overtreatment and missed cases. Subsequently, a rapid lateral flow assay with fluorescence-based detection (NG-LFA) with a prototype reader was developed forN. gonorrhoeaedetection showing excellent performance and high usability; however, a better understanding is needed for device implementation and integration into clinics.Methods: A qualitative, time-series assessment using 66 in-depth interviews was conducted among 25 trained healthcare workers involved in the implementation of the NG-LFA. Findings were informed by the Normalization Process Theory (NPT) as per relevant contextual (strategic intentions, adaptive execution, and negotiation capacity) and procedural constructs (coherence, cognitive participation, collective action, reflexive monitoring) to examine device implementation within primary healthcare levels. Interviews were audio-recorded, transcribed, and then analyzed using a thematic approach guided by NPT to interpret results.Results: Overall, healthcare workers agreed that STI POCT could guide better STI clinical decision-making, with consideration for clinic integration such as space constraints, patient flow, and workload. Perceived NG-LFA benefits included enhanced patient receptivity and STI knowledge. Further, healthcare workers reflected on the suitability of the NG-LFA given current limitations with integrated primary care. Recommendations included sufficient STI education, and appropriate departments for first points of entry for STI screening.Conclusions: The collective action and participation by healthcare workers in the implementation of the NG-LFA revealed adaptive execution within the current facility environment including team compositions, facility-staff receptivity, and STI management experiences. User experiences support future clinic service integration, highlighting the importance of further assessing patient-provider communication for STI care, organizational readiness, and identification of relevant departments for STI screening.

12 May 2025 in Clinical Infectious Diseases
Verified
Journal Article
Open access
JCJoshua M Chevalier
Joshua M Chevalier
MHMegan A Hansen
Megan A Hansen
BBBenjamin Blumel
Benjamin Blumel
VCVeronicah Mbaire Chuchu
Veronicah Mbaire Chuchu
BGBirgitta Gleeson
Birgitta Gleeson
KGKyra H Grantz
Kyra H Grantz
Background: Limited diagnostic access in resource-limited settings contributes to poor health outcomes among bacterial sepsis patients and the spread of antimicrobial resistance (AMR). Molecular diagnostic profiling of AMR may enable faster targeting of antibiotic therapies, improving clinical outcomes, reducing AMR development, and saving costs. Methods: We modeled the impact of a culture-dependent molecular test for pathogen identification and resistance testing among hospitalized bloodstream infection patients to guide effective and cost-efficient implementation of these tools. We evaluated patient mortality, antibiotic use, hospital-associated infections, hospital days, and costs under the standard of care (empiric therapy, blood culture, phenotypic susceptibility testing) compared with molecular diagnostics by varying culture and susceptibility testing coverage, culture turnaround time, and AMR prevalence. Results: The greatest impact of the molecular test occurred with 100% diagnostic coverage, shorter culture turnaround time, and high AMR prevalence, reducing up to 6% of deaths (interquartile range [IQR], 0%–12.1%), 5% of hospital days (IQR, 0.1%–10.7%), and 21% of days on inappropriate antibiotic therapy (IQR, 18.2%–24.4%). The minimum cost per molecular test performed, offset by cost savings, ranged from $109 in India to $585 in South Africa across all modeled scenarios. Conclusions: In high AMR burden settings with blood culture infrastructure supporting fast turnaround times, a molecular test could improve health outcomes of bloodstream infection. Impact is limited by delayed turnaround times and the effectiveness of empiric therapy. Molecular diagnostics implemented at $100 or less can generate healthcare-system cost savings, supporting their adoption to improve health outcomes and reduce AMR while remaining cost-neutral.

29 October 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
JCJoshua M Chevalier
Joshua M Chevalier
MHMegan A Hansen
Megan A Hansen
KGKyra H Grantz
Kyra H Grantz
BGBirgitta Gleeson
Birgitta Gleeson
BBBenjamin Blumel
Benjamin Blumel
BNBrooke Nichols
Brooke Nichols
Background: Sepsis contributes to nearly 50% of neonatal deaths in resource-limited settings. Accurate, timely diagnosis can improve outcomes, reduce inappropriate antibiotic use, and save healthcare costs. We aimed to determine the minimum technical requirements and cost of a point-of-care test (POCT) for neonatal sepsis to be clinically effective in hospitals and community settings in low-resource settings. Methods: We modeled the diagnosis and treatment of hospitalized neonates and infants at primary care facilities with suspected sepsis. Health outcomes (mortality, hospital stays, and healthcare-associated infections [HAIs]) were compared under empiric treatment with varied blood culture scenarios to a POCT. Test performance, bacterial infection prevalence, and discharge criteria were varied. A threshold economic analysis identified maximum allowable costs for a cost-neutral POCT. Results: A POCT could reduce neonatal deaths significantly at hospitals (up to 19%) and community levels (up to 70%), compared with baseline, by enabling faster therapy initiation and reducing unnecessary hospitalizations and HAIs. Healthcare costs could drop by 17%–43% in hospitals and 48%–81% in primary care settings. A POCT priced at $21 for hospitals and $3 for community use could remain cost-neutral. Conclusions: A POCT for neonatal sepsis, even with moderate accuracy, could improve outcomes by accelerating diagnosis, supporting antibiotic stewardship, and lowering costs. High sensitivity is essential to minimize deaths from missed diagnoses and delayed antibiotic therapy. Our results suggest 85% sensitivity and 80% specificity for hospitalized neonates, and 90% sensitivity and 70% specificity in primary care settings are the minimum necessary technical requirements for the POCT.

22 February 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BBBenjamin Blümel
Benjamin Blümel
MDMichaela Diercke
Michaela Diercke
DSDaniel Sagebiel
Daniel Sagebiel
AGAndreas Gilsdorf
Andreas Gilsdorf
The German Infection Protection Act requires notifying certain cases of infectious diseases to local health departments (LHD) in Germany. LHDs transmit notifications meeting case definitions to the national health authority, where the proportion of discarded notifications is not known. The proportion of discarded cases at the level of LHDs can be expressed as the positive predictive value (PPV) of the notification system. The PPV can be used to assess the efficiency of the system. We quantified the proportion of discarded notifications to calculate the PPV of the German notification system at the level of LHDs using electronic notification data from Berlin LHDs from 2012. We also analysed reasons for discarding notifications by reviewing notification forms. Data was available from eight LHDs (67%) receiving 10,113 notifications in 2012. Overall PPV was 89% (minimum-maximum = 77–97% across LHDs) and ranging from 30% (Hepatitis B) to 99% (Rotavirus). Of 166 individual investigation forms 84% were on hepatitis B or C cases, most of them discarded because of previously diagnosed chronic disease. LHDs investigate many notifications that do not lead to public health action and useful surveillance data leading to inefficient use of resources. Adaptation of case definitions or the legal framework concerning notifications may increase the efficiency of the notification system and lead to better use of data from notified cases.